A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney functionHiddo J.L. Heerspink, Dánae Duana Ávila, Glenn M. Chertow et al.|Kidney International|2021Cited by 95
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary AnalysisPeter Rossing, Márcio Krakauer, George L. Bakris et al.|Diabetes Care|2025Cited by 16